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Abstract
BACKGROUND—Cancer survival rates are important to evaluate cancer care, identify disease 
patterns, and to estimate the probability of death due to cancer. To date, survival rates have been 
calculated using other data sets with limited population coverage that may not be able to fully 
identify differences by treatment, geographic regions, and racial or ethnic groups. Data from the 
Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries 
(NPCR) have not previously been used to calculate relative survival rates within the United States.
METHODS—Data from CDC's November 2011 submission for 21 state population-based central 
cancer registries, representing 50% of the U.S. population, were included in this analysis. This 
paper presents relative survival rates for diagnosis years 2000-2007 with follow-up through 2008.
RESULTS—The relative survival rate for all cancers and races combined was 65.0%; 65.3% for 
males, 64.8% for females. Blacks had a lower relative survival rate than whites, except for lung 
and bronchus. For all cancers, the <45 age groups had the highest relative survival rates, except for 
black males.
DISCUSSION—For all cancer primary sites combined for 2000-2007, the CDC NPCR five-year 
relative survival rate is comparable to that reported by the National Cancer Institute and the 
Canadian Cancer Registry. This analysis presents, for the first time, relative survival rates for half 
of the total U.S. population and demonstrates that reliable survival rates can be calculated using 
CDC's NPCR data now and in the future.
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Other publications (1-7) have shown the importance of cancer survival rates to evaluate 
cancer care, identify disease patterns, and to estimate the probability of death due to cancer. 
This information is of interest to clinicians, patients, public health practitioners, and 
researchers as well as the public. To date, survival rates have been calculated using other 
data sets with limited population coverage that may not be able to fully identify differences 
by treatment, geographic regions, and racial and ethnic groups (1).
Estimates of current U.S. survival rates are based on data from the National Cancer Institute 
(NCI) Surveillance, Epidemiology and End Results (SEER) program or from special 
studies (1, 8-10). The NCI data set covers approximately 14% or 28% of the U.S. population, 
depending on the table referenced (1). Until the preparation of this report, data from the 
Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries 
(NPCR) have not been used to calculate relative survival rates. This report demonstrates that 
researchers can also use NPCR data to calculate reliable relative survival rates that helps to 
provide a more comprehensive picture of cancer survival in the United States.
CDC's NPCR was established in 1992 to support the implementation and enhancement of 
population-based central cancer registries in U.S. states and territories (11). CDC currently 
supports 45 states, the District of Columbia, Puerto Rico, and the Pacific Island Jurisdictions 
covering 96% of the U.S. population. CDC and NCI jointly support five of these, while the 
remaining five states are funded by NCI alone.
Beginning in 2001, NPCR-funded grantees began reporting incidence data to CDC (12). 
Currently, CDC and NCI cancer surveillance data together are the foundation of national 
data on cancer trends including risks in special populations, the design and evaluation of 
public health interventions, many clinical and etiologic epidemiologic studies, and quality of 
care evaluation studies (13).
In order to understand cancer prognosis and improve control of all types of cancer in the 
United States, the survival rates for specific cancer sites and subpopulations may be 
monitored over time. Survival data are critical for evaluating the progress and impact of 
early detection and screening programs, comprehensive cancer control plans, and 
interventions from other sources (1-4). As one available resource, survival data assists in 
identifying high-risk population groups which may lead to more effective and 
comprehensive program planning.
Methods
The relative survival rate is the ratio of the observed survival in a patient cohort divided by 
the expected survival of a comparable cancer-free group from the general population in the 
absence of the specific cancer (1). A data set of invasive cancer cases for diagnosis years 
2000-2007 from people ages 20-99 years was created using the NPCR November 2011 data 
submission file. We excluded data from 23 registries that either did not meet NPCR data 
quality standards for inclusion in the United States Cancer Statistics (14) or did not conduct 
active case follow-up or linkage with the National Center for Health Statistics’ National 
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Death Index (NDI) through the 2008 death file. In 2006, the NPCR entered into an intra-
agency agreement with NDI allowing registries to link with that database on a regular basis. 
An additional 4 registries requested their data not be used in survival analyses at this time. 
The quality and completeness of individual data items used in this analysis were previously 
conducted and reported elsewhere (15). Due to difficulties with data collection following 
Hurricanes Katrina and Rita in 2005, we excluded data for July 1 through December 31, 
2005 for Alabama, Louisiana, Mississippi, and Texas, according to established practices (1). 
Twenty-one NPCR registries were included in the analysis representing 50% of the U.S. 
population.
Where incomplete, the full date of diagnosis and date of last contact were imputed (16). 
Additionally, cases not linking to the state death files and NDI were presumed to be alive 
and the date of last contact was set to December 31, 2008. Cases with multiple primary 
cancers were included in the dataset, though only the first primary was included in 
calculating survival rates for all cancer sites combined. Where a patient had multiple 
primaries of the same site only the first primary was included in the calculations for that 
primary site (17-18). We excluded cancer cases with unknown age or sex (1,873; 0.03%) and 
those identified solely on the basis of a death certificate or autopsy (75,253; 1%).
Using state-specific life tables by black and white race and sex, provided by the National 
Center for Health Statistics, (19) we calculated 5-year survival rates for cases diagnosed in 
2000-2007 with follow-up through 2008 following a process described by Paul Dickman (2) 
that includes the Ederer II relative survival methodology. Rates were calculated for all 
cancer primary sites combined and 23 specific primary sites, grouped by the SEER Site 
Recode (1), by survival interval, sex, race, age group, and SEER Summary stage (local, 
regional, distant) (20). The 23 specific primary site groups were selected due their frequency, 
screening amenability, and modifiable risk factors. All primary sites combined and the top 
ten primary site groups are shown in Table 1. Life tables are not available for races other 
than white and black populations, therefore survival rates are calculated for these races only. 
The age groups are defined as <45, 45-54, 55-64, 65-74, and 75 and older. All analyses were 
performed using SAS software version 9.3 (SAS Institute, Inc., Cary, North Carolina). Five-
year relative survival rates are presented in Tables 1-3 for all cancer primary cancer sites 
combined and select specific primary sites by site, sex, age, and stage groups.
Results
More than five million cancer cases, from diagnosis years 2000-2007, were included in this 
dataset, and were evenly distributed between males and females. Cases for whites 
represented 85% of the total cases with 10% for blacks. The population from the 21 states 
was more than 300 million with a similar distribution for the white and black populations, 
81% and 12% respectively (data not shown).
We present 5-year relative survival rates for all sites combined and specific cancer primary 
sites by sex and race in Table 1. The 5-year relative survival rate for all cancer primary sites 
combined, all races combined, was 65.0%; 65.3% for males and 64.8% for females. For all 
cancers and each specific cancer site, blacks had a lower 5-year relative survival rate than 
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whites, except lung and bronchus where the rate for black males was higher than white 
males and males of all races; 17.0%, 14.8%, and 14.7% respectively. Of the specific cancer 
sites analyzed, thyroid cancer had the highest relative 5-year survival rate for males and 
females combined (96.4%) and for females alone (97.6%). Prostate cancer had the highest 
relative 5-year survival rate for males (98.5%). The lowest rates were seen for lung and 
bronchus, ranging from 12.5% for black women to 20.4% for white women.
Table 2 shows 5-year relative survival rates by age at diagnosis and for all primary sites 
combined and the top four primary sites. For all cancer primary sites combined, the <45 age 
groups had the highest 5-year relative survival rates, except black males where the 65-74 age 
group had the highest rate. The 45-54 age groups had the highest relative survival rates for 
colon and rectum, except black males where the 65-74 age group had the highest rate. For 
lung and bronchus, the <45 age groups also had the highest relative survival rates. Age 
group 65-74 has the highest relative survival rates for prostate and female breast for all races 
combined, whites, and blacks.
Five-year relative survival rates by cancer stage at diagnosis are presented in Table 3. The 
highest rates are seen in the localized stage group and lowest rates in the distant stage group. 
This pattern is seen for all cancers combined and each specific cancer primary site analyzed. 
Blacks have lower 5-year relative survival rates than whites for all cancers combined, colon 
and rectum, lung and bronchus (except distant stage), and female breast. The relative 
survival rates for prostate for blacks are equal to or slightly higher than those seen for 
whites.
Discussion
This report provides 5-year relative survival rates for the largest proportion of the total U.S. 
population ever presented. While existing survival estimates cover 14% to 28% of the U.S. 
population(1), the NPCR data represents nearly double this population coverage and, when 
combined with NCI's data in the future, the two programs together, have the capability of 
covering 100% of the nation.
For all cancers combined for 2000-2007, the NPCR 5-year relative survival rate is 65.0%, 
comparable to that available from the NCI for the same time period, 67.1%, and the 
Canadian Cancer Registry, 62.0% for 2004-2006 (3, 21). As expected, lower age groups have 
the highest survival as does localized stage at diagnosis. These trends are also comparable to 
those reported by NCI.
While SEER data have been a trusted and valued source of cancer survival information for 
decades, only a few states within the United States have previously been able to monitor 
their local cancer survival rates,(16) an essential tool in evaluating local cancer control 
initiatives. The addition of survival estimates from NPCR programs for national estimates 
will also provide more generalizable data, particularly for certain currently under-
represented minority populations (22). The NPCR program's expansive geographic coverage 
will also allow survival rates to be calculated for many rural populations and by geographic 
region. Although, through exclusions, the current report is not derived from the entire NPCR 
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program, the data reported here provide for the most complete description of the cancer 
burden in the United States to date (3). Furthermore, the NPCR data set supports the analysis 
of rare cancers, such as retinoblastoma or primary fallopian tube cancers (23). As the number 
of NPCR registries that link to the National Death Index increases, the quality and 
completeness of data on relative survival in the U.S. population will continue to grow as will 
our understanding of the impact of geographic, racial/ethnic, and medical care variations.
CDC's NPCR registries currently meet established standards for high quality data (14) and 
most, but not all, conduct either active case follow-up activities or linkages with the NDI in 
order to obtain and update vital status information. This means that NPCR data are now in a 
position where valid and reliable relative survival rates can be produced and published. 
However, additional work continues so that all NPCR registries will conduct data linkages 
with NDI on a regular basis. In addition to the inclusion requirements related to data quality 
and follow-up, NPCR grantees have the option to decline inclusion in the survival analyses 
at this time. CDC continues to encourage NPCR grantees to meet the USCS data quality and 
completeness criteria, to conduct follow-up data linkages, update their database following 
those linkages prior to the NPCR data submission, and allow inclusion of their data in these 
analyses.
CONCLUSION
The NPCR data are a robust data set available for calculating reliable 5-year relative 
survival rates that are not likely to be affected by small case counts. CDC will be including 
relative survival rates for a subset of NPCR programs in subsequent editions of the United 
States Cancer Statistics Web-Based Report (14). The combination of survival estimates from 
both NCI and CDC will allow for more complete monitoring of any upcoming Healthy 
People objectives to increase the percentage of persons with cancer living five years or 
longer after diagnosis (24).
Acknowledgments
The findings and conclusions in this report are those of the authors and do not necessarily represent the official 
position of the Centers for Disease Control and Prevention.
REFERENCES
1. Howlader, N.; Noone, AM.; Krapcho, M.; Garshell, J.; Neyman, N.; Altekruse, SF.; Kosary, CL.; 
Yu, M.; Ruhl, J.; Tatalovich, Z.; Cho, H.; Mariotto, A.; Lewis, DR.; Chen, HS.; Feuer, EJ.; Cronin, 
KA., editors. SEER Cancer Statistics Review, 1975-2010. National Cancer Institute; Bethesda, MD: 
http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to 
the SEER web site, April 2013
2. Dickman PW, Adami HO. Interpreting trends in cancer patient survival. Journal of Internal 
Medicine. 2006; 260:103–117. [PubMed: 16882274] 
3. Ellison LF, Wilkins K. An update on cancer survival. Statistics Canada. 2010; 21(3) Catalogue no. 
82-003-XPE. 
4. Compton, CC., et al., editors. AJCC Cancer Staging Atlas: A Comparison to the Seventh Editions of 
the AJCC Cancer Staging Manual and Handbook. American Joint Committee on Cancer; 2012. DOI 
10.1007/978-1-4614-2080-4_2
Wilson et al. Page 5









5. Allemani C, Rachet B, Weir HK, et al. Colorectal cancer survival in the USA and Europe: a 
CONCORD high-resolution study. BMJ Open. 2013; 3:e003055.
6. Allemani C, Sant M, Weir HK, et al. Breast cancer survival in the US and Europe: a CONCORD 
high-resolution study. Int J Cancer. 2013; 132:1170–1181. [PubMed: 22815141] 
7. Coleman MP, Quaresman M, Berrino F, et al. Cancer survival in five continents: a worldwide 
population-based study (CONCORD). Lancet Oncol. 2008; 9:730–56. [PubMed: 18639491] 
8. Abdollah F, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United 
States: a trend analysis. CancerEpidemiol. Jun; 2013 37(3):219–25.
9. Price GL, Davis KL, Karve S, Pohl G, Walgren RA. Survival Patterns in United States (US) 
Medicare Enrollees with Non-CML Myeloproliferative Neoplasms (MPN). PLoS ONE. 2014; 
9(3):e90299. doi:10.1371/journal.pone.0090299. [PubMed: 24618579] 
10. Schymura MJ, Kahn AR, German RR, Hsieh MC, Cress RD, Finch JL, Fulton JP, Shen T, Stuckart 
E. Factors associated with initial treatment and survival for clinically localized prostate cancer: 
results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer. 2010; 10:152. 
[PubMed: 20403178] 
11. Hutton MD, Simpson LD, Miller DS, Weir HK, McDavid K, Hall HI. Progress Toward 
Nationwide Cancer Surveillance: An Evaluation of the National Program of Cancer Registries, 
1994-1999. J Registry Manage. 2001; 28(3):113–120.
12. Thoburn KK, German RR, Lewis M, Nichols P, Ahmed F, Jackson-Thompson J. Case 
completeness and data accuracy in the Centers for Disease Control and Prevention's National 
Program of Cancer Registries. Cancer. 2007; 109:1607–1616. doi: 10.1002/cncr.22566. [PubMed: 
17343277] 
13. Division of Cancer Prevention and Control. Centers for Disease Control and Prevention; 
2004/2005. Cancer Registries: The Foundation for Cancer Prevention and Control Fact Sheet.. 
14. U.S. Cancer Statistics Working Group. United States Cancer Statistics. 1999–2010 Incidence and 
Mortality Web-based Report. U.S. Department of Health and Human Services, Centers for Disease 
Control and Prevention and National Cancer Institute; Atlanta: 2013. Available at: www.cdc.gov/
uscs
15. Wilson R, O'Neil ME, Ntekop E, Zhang K, Ren Y. Coding Completeness and Quality of Relative 
Survival-Related Variables in the National Program of Cancer Registries Cancer Surveillance 
System 1995–2008. 2014 In progress. 
16. Johnson CJ, Weir HK, Yin D, Niu X. The Impact of Patient Follow-up on Population-based 
Survival Rates. J Registry Manage. 2010; 37(3):86–103.
17. Ellison LF. Measuring the Effect of Including Multiple Cancers in Survival Analyses Using Data 
from the Canadian Cancer Registry. Cancer Epidemiology. 2010; 34:550–555. [PubMed: 
20638928] 
18. Brenner H, Hakulinen T. Patients with previous cancer should not be excluded in international 
comparative cancer survival studies. Int J Cancer. 2007; 121:2274–2278. [PubMed: 17594692] 
19. Wei, R.; Anderson, RN.; Curtin, LR.; Arias, E. U.S. decennial life tables for 1999–2001: State life 
tables. National vital statistics reports. Vol. 60. National Center for Health Statistics; Hyattsville, 
MD: 2012. 
20. Young, JL., Jr; Roffers, SD.; Ries, LAG.; Fritz, AG.; Hurlbut, AA., editors. SEER Summary 
Staging Manual - 2000: Codes and Coding Instructions. National Cancer Institute; Bethesda, MD: 
2001. NIH Pub. No. 01-4969
21. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat 
Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana 
Cases, Nov 2011 Sub (1973-2009 varying) - Linked To County Attributes - Total U.S., 1969-2010 
Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance 
Systems Branch, released April 2012, based on the November 2011 submission.
22. Merrill RM, Dearden KA. How Representative are the Surveillance, Epidemiology, and End 
Results (SEER) Program Cancer Data of the United States? Cancer Causes Control. 2005; 15(10):
1027–1034. [PubMed: 15801487] 
23. Stewart SL, Wike JM, Foster SL, Michaud F. The incidence of primary fallopian tube cancer in the 
United States. Gynecol Oncol. Dec; 2007 107(3):392–7. Epub 2007 Oct 24. [PubMed: 17961642] 
Wilson et al. Page 6









24. US Department of Health and Human Services. Health people 2020. US Department of Health and 
Human Services; Washington, DC: 2011. Available at http://www.healthypeople.gov/2020/
topicsobjectives2020/default.aspx
Wilson et al. Page 7

















Wilson et al. Page 8
Table 1
CDC NPCR-CSSa 5-Year Relative Survival (Percent) by SEER Cancer Primary Site Recodeb, Racec, and Sex, 
2000-2007
All Races Whites Blacks
Cancer Site Both Sexes Males Females Both Sexes Males Females Both Sexes Males Females
All Sites Combined 65.0 65.3 64.8 65.8 65.8 65.9 59.3 62.0 56.2
Breast (female) - - 88.3 - - 89.5 - - 77.5
Colon & rectum 63.9 63.8 63.9 64.3 64.2 64.3 57.0 56.1 57.7
Corpus & uterus - - 80.7 - - 82.8 - - 58.9
Kidney & renal pelvis 69.2 69.0 69.4 69.1 69.0 69.3 67.3 67.0 67.8
Lung & bronchus 17.3 14.7 20.3 17.4 14.8 20.4 14.3 17.0 12.5
Melanoma of skind 89.6 87.4 92.4 89.2 87.0 92.1 ~ ~ ~
Non-Hodgkin lymphoma 65.7 64.0 67.6 66.0 64.5 67.8 58.1 54.7 62.1
Prostate - 98.5 - - 98.5 - - 95.7 -
Thyroid 96.4 92.6 97.6 96.5 92.4 97.8 94.0 88.2 95.2
Urinary bladder 75.9 77.3 71.6 76.2 77.3 72.7 63.0 68.1 53.6
aCenters for Disease Control and Prevention National Program of Cancer Registries – Cancer Surveillance System
b
Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis 
DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://
seer.cancer.gov/csr/1975 2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
c
Life tables are not available to calculate survival rates on populations other than Whites and Blacks
d
Melanoma of skin survival rates are limited to Whites.
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Table 2
CDC NPCR-CSSa 5-Year Relative Survival (Percent) by Age at Diagnosis, SEER Cancer Primary Site 
Recodeb, Race, and Sex, 2000-2007
Age at Diagnosis Whites Blacks
Males Females Males Females
All Sites Combined Ages <45 76.5 84.2 59.9 71.8
Ages 45-54 66.7 78.0 58.1 63.7
Ages 55-64 68.4 69.8 65.0 57.1
Ages 65-74 67.8 61.2 67.6 50.8
Ages 75+ 55.7 49.4 51.8 38.9
Colon and Rectum Ages <45 67.1 71.0 58.5 60.8
Ages 45-54 69.1 71.2 59.1 64.6
Ages 55-64 67.7 69.8 58.3 61.3
Ages 65-74 66.1 67.3 59.2 60.6
Ages 75-99 57.7 58.3 45.6 47.8
Lung and Bronchus Ages <45 23.8 29.2 19.1 22.7
Ages 45-54 17.0 26.0 13.4 19.4
Ages 55-64 16.5 24.1 13.5 19.0
Ages 65-74 15.6 21.5 12.5 16.7
Ages 75-99 11.0 14.4 8.6 11.9
Whites Blacks
Prostate Ages <45 95.1 96.4
Ages 45-54 97.7 96.7
Ages 55-64 98.9 97.3
Ages 65-74 100.0 98.5
Ages 75-99 93.1 84.4
Female Breast Ages <45 88.0 76.3
Ages 45-54 90.4 78.1
Ages 55-64 90.2 78.6
Ages 65-74 91.0 80.3
Ages 75-99 87.2 73.0
aCenters for Disease Control and Prevention National Program of Cancer Registries – Cancer Surveillance System
b
Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis 
DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://
seer.cancer.gov/csr/1975 2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
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Table 3
CDC NPCR-CSSa 5-Year Relative Survival (Percent) by SEER Cancer Primary Site Recodeb, SEER 
Summary Stage at Diagnosis, Race, and Sex, 2000-2007
SEER Summary Stage at Diagnosis Whites Blacks
Males Females Males Females
All Sites Combined Localized 91.7 91.0 92.2 84.6
Regional 57.0 66.5 51.5 58.5
Distant 24.8 25.7 20.3 21.7
Colon and Rectum Localized 88.1 88.7 82.5 84.9
Regional 67.8 68.5 63.7 63.6
Distant 11.2 13.0 9.4 10.5
Lung and Bronchus Localized 45.1 55.5 40.1 49.9
Regional 19.6 25.5 17.9 23.1
Distant 3.2 4.5 3.7 4.6
Whites Blacks
Prostate Localized 100.0 100.0
Regional 98.6 98.6
Distant 28.8 30.9
Female Breast Localized 98.1 92.3
Regional 84.1 72.2
Distant 25.6 16.8
aCenters for Disease Control and Prevention National Program of Cancer Registries – Cancer Surveillance System
b
Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis 
DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://
seer.cancer.gov/csr/1975 2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.
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